<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"> <channel>  <title><![CDATA[Clayton Utz | Healthcare and Life Sciences - Publications]]></title>  <link>http://www.claytonutz.com/industry/healthcare_and_life_sciences/publications.page</link>  <description/>  <copyright><![CDATA[(c) Clayton Utz 2009]]></copyright>  <image>   <title><![CDATA[Clayton Utz]]></title>   <link>http://www.claytonutz.com/</link>   <url>http://www.claytonutz.com/images/logo.png</url>  </image>  <language>en-au</language> <item><guid>http://www.claytonutz.com/publications/news/201005/26/implementing_the_trips_protocol-public_comment_sought.page</guid><title><![CDATA[Implementing the TRIPS Protocol - public comment sought]]></title><link>http://www.claytonutz.com/publications/news/201005/26/implementing_the_trips_protocol-public_comment_sought.page</link><description><![CDATA[IPAustralia is seeking comment on the implementation of the TRIPS Protocol, which would make compulsory licences for pharmaceutical products easier to grant.]]></description><pubDate>Wed, 26 May 2010 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20090930/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20090930/home.page</link><description><![CDATA[This issue includes: One for all, and all for one? A unified approach to therapeutic goods promotion; There was movement at the station: the Australian consumer law reforms are being enacted into law; Regulatory reform: In brief; What's up doc? The doctor's duty of care to third parties; European developments: to regulate or not to regulate - that is the question?;]]></description><pubDate>Wed, 30 Sep 2009 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200906/30/clayton_utz_partner_appointed_to_advisory_council.page</guid><title><![CDATA[Clayton Utz partner appointed to Advisory Council]]></title><link>http://www.claytonutz.com/publications/news/200906/30/clayton_utz_partner_appointed_to_advisory_council.page</link><description><![CDATA[Clayton Utz partner Robyn Baker has been appointed to the Australian government's Australian Research Council (ARC) Advisory Council.]]></description><pubDate>Tue, 30 Jun 2009 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20081202/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20081202/home.page</link><description><![CDATA[This issue includes: Product liability and class actions: Pharma and medical devices in the litigation league table; Regulation and reputation: The legal pitfalls; Cost recovery arrangements for PBS-listed medicines and vaccines;]]></description><pubDate>Tue, 02 Dec 2008 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20080424/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20080424/home.page</link><description><![CDATA[This issue includes: Educator or promoter - Are you at risk of an identity crisis?; Increased transparency for corporate sponsorship of doctors' education; Is a unified consumer law in sight?; Developments in EU and UK consumer protection: a class act?; Pharmaceutical patent infringement - interlocutory injunctions now easier to obtain;]]></description><pubDate>Thu, 24 Apr 2008 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20070813/home.page</guid><title><![CDATA[Pharmaceutical Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/pharmaceutical_insights/20070813/home.page</link><description><![CDATA[This issue includes: ANZTPA abandoned for now; The future with the Medicines Australia Code of Conduct; Reform of the private health insurance regime; More rigorous IVD regime one step closer - but will it be trans-Tasman?; Labelling of complementary medicines; Meet the team; Australia's High Court grapples with the issue of obviousness again; Patenting enantiomers - court decides there is nothing sinister;]]></description><pubDate>Mon, 13 Aug 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200706/18/pbs_reforms_introduced_to_parliament.page</guid><title><![CDATA[PBS reforms introduced to Parliament]]></title><link>http://www.claytonutz.com/publications/news/200706/18/pbs_reforms_introduced_to_parliament.page</link><description><![CDATA[The Government's plan to reform the Pharmaceutical Benefits Scheme ("PBS") has gained further momentum with the introduction of the National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007 into Federal Parliament on 24 May 2007.]]></description><pubDate>Mon, 18 Jun 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200705/04/draft_anztpa_bill-what_does_it_say.page</guid><title><![CDATA[Draft ANZTPA Bill - what does it say?]]></title><link>http://www.claytonutz.com/publications/news/200705/04/draft_anztpa_bill-what_does_it_say.page</link><description><![CDATA[As you would know, an exposure draft of the Therapeutic Products Bill 2007 ("Bill") governing the regulation of therapeutic products under the new Australia New Zealand Therapeutic Products Authority ("ANZTPA") was released for public consultation and comment on 2 April 2007. This is the first of a package of Bills to be released, to give effect to the Agreement between the Australian and New Zealand Governments for the Establishment of a Joint Scheme for the Regulation of Therapeutic Products ("the Agreement").]]></description><pubDate>Fri, 04 May 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20070402/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20070402/home.page</link><description><![CDATA[This issue includes: Update on ANZTPA - the Draft Advertising Rule; Latest news on the Therapeutic Products and Medicines Bill; Changes to the Good Manufacturing Practice clearance guidelines of overseas medicine manufacturers; Meet the Team; Defences to liability for defective products: Is there an international standard?; Quick dose; When does a product contain a pharmaceutical substance for the purposes of a patent extension?; Pharmaceutical patent term extensions - Full Federal Court defines "first regulatory approval date";]]></description><pubDate>Mon, 02 Apr 2007 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20061201/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20061201/home.page</link><description><![CDATA[This issue includes: ANZTPA: Second phase of consultation is underway; Advertising Code 2006: Further steps towards a Trans-Tasman scheme; Meet the team: Dr Teresa Baker, Legal Co-ordinator - Pharmaceutical Regulatory Affairs, Sydney; Quick dose; The challenges of interlocutory injunctions: CSL Ltd v GlaxoSmithKline Australia; Wrongful life claims - recent decisions and further implications for the life sciences industry; Update on the TGN1412 trial: Review and recommendations of the Expert Scientific Group; The end of the rogue trader? Developments in UK consumer protection; Will springboarding changes have a significant impact on the Australian pharmaceutical industry?; Can a pharmaceutical patent term extension, once granted, be shortened or cancelled?; Pharmaceutical patent term extensions - eligibility, application deadline and length clarified;]]></description><pubDate>Fri, 01 Dec 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200609/04/cu_specialist_appointed_to_peak_government_review_body.page</guid><title><![CDATA[CU specialist appointed to peak government review body]]></title><link>http://www.claytonutz.com/publications/news/200609/04/cu_specialist_appointed_to_peak_government_review_body.page</link><description><![CDATA[Clayton Utz regulatory specialist Dr Teresa Baker has been appointed to the NSW division of the Administrative Appeals Tribunal effective 24 August. Federal Attorney-General Philip Ruddock announced Dr Baker as one of eight new appointees to the Tribunal, the body charged with reviewing decisions of Australian government departments and agencies. Dr Baker joins the Tribunal as a part-time member, joining four other NSW appointees.]]></description><pubDate>Mon, 04 Sep 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200608/29/international_comparative_legal_guide_to_pharmaceutical_advertising_2006.page</guid><title><![CDATA[International Comparative Legal Guide to: Pharmaceutical Advertising 2006]]></title><link>http://www.claytonutz.com/publications/news/200608/29/international_comparative_legal_guide_to_pharmaceutical_advertising_2006.page</link><description><![CDATA[Product liability law experts, Clayton Utz partner Colin Loveday and senior associate Greg Williams, have contributed the Australian chapter to the "International Comparative Legal Guide to: Pharmaceutical Advertising 2006". Contributions are by invitation only, and Colin and Greg are the only Australian lawyers featured.]]></description><pubDate>Tue, 29 Aug 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060731/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060731/home.page</link><description><![CDATA[This issue includes: STOP PRESS!; Consultation Forums on ANZTPA Held - Implications of the Joint Scheme for Industry; Quick dose - regulatory developments in Australia and overseas; Wrongful life claims - recent decisions and the implications for the life sciences industry; Conducting clinical trials with biological medicines - lessons learnt from the UK TGN1412 trial; Once weekly method of treatment not a patentable invention; Is an injunction restraining further infringement automatic when a patent is held infringed?; Patent quips: Edited by Wayne Condon;]]></description><pubDate>Mon, 31 Jul 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200605/30/a_strong_dose_of_regulation_for_pharmaceuticals_sector.page</guid><title><![CDATA[A strong dose of regulation for pharmaceuticals sector]]></title><link>http://www.claytonutz.com/publications/news/200605/30/a_strong_dose_of_regulation_for_pharmaceuticals_sector.page</link><description><![CDATA[Companies operating in the pharmaceuticals and medical devices sectors will need to be extra vigilant in maintaining good business and risk management practices following changes to the regulatory regime under which they operate, according to a leading corporate lawyer.]]></description><pubDate>Tue, 30 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200605/22/be_prepared_new_tga_enforcement_powers_start_soon.page</guid><title><![CDATA[Be prepared! New TGA enforcement powers start soon]]></title><link>http://www.claytonutz.com/publications/news/200605/22/be_prepared_new_tga_enforcement_powers_start_soon.page</link><description><![CDATA[Australia now has a strengthened regime within the Australian therapeutic goods market including a tiered regime of criminal offences and civil penalties, higher penalties, and liability for "executive officers", following the passage of the Therapeutic Goods Amendment Act 2006. Most of the changes will come into effect on 31 May 2006, breathing new life into the powers of the Therapeutic Goods Authority ("TGA") to enforce the Therapeutic Goods Act 1989 (Cth).]]></description><pubDate>Mon, 22 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060509/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060509/home.page</link><description><![CDATA[This issue includes: Australia New Zealand Therapeutic Products Authority - Full steam ahead; Quick dose; Tort law reform - The final chapter; The NHMRC Amendment Bill 2006 - greater autonomy and transparency; Can you patent a method of medical diagnosis or treatment?; Added protection for US method patents could restrict local research; The Omnitrope experience . Is it STOP or GO for follow-on biologicals in Australia?; Patent quips;]]></description><pubDate>Tue, 09 May 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060228/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20060228/home.page</link><description><![CDATA[This issue includes:]]></description><pubDate>Tue, 28 Feb 2006 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20051206/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20051206/home.page</link><description><![CDATA[This issue includes: Transparency reforms to the Pharmaceutical Benefits Scheme introduced under the FTA; Food/therapeutic goods interface: Can apples be compared to orange pills?; Quick dose; 8  rules of comparative advertising; Code of best practice for reporting by life science companies; Is Australian law on patents and experimental use about to be clarified?;]]></description><pubDate>Tue, 06 Dec 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200510/05/clayton_utz_partner_joins_metabolic_board.page</guid><title><![CDATA[Clayton Utz partner joins Metabolic board]]></title><link>http://www.claytonutz.com/publications/news/200510/05/clayton_utz_partner_joins_metabolic_board.page</link><description><![CDATA[The appointment of Clayton Utz life sciences partner Robyn Baker to the board of Melbourne-based biotech Metabolic Pharmaceuticals Limited as a non-executive director confirms widespread recognition of Clayton Utz as the leading Australasian law firm in the life sciences sector.]]></description><pubDate>Wed, 05 Oct 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050921/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050921/home.page</link><description><![CDATA[This issue includes: The TGA gets set to get tough: Likely new enforcement options; Code 2005: The first Australian regulatory step towards a trans-Tasman scheme; Advertising prices of prescription products to be made clearer; Quick dose; Australian consumer product safety: fundamental reform not needed, just improvements; Health information privacy - Another layer of protection; If you dice the mice you must pay the price; The US Supreme Court decides an exceptional patent case;]]></description><pubDate>Wed, 21 Sep 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200508/29/a_strong_dose_of_regulation_set_to_shake_up_pharmaceuticals_sector.page</guid><title><![CDATA[A strong dose of regulation set to shake up pharmaceuticals sector]]></title><link>http://www.claytonutz.com/publications/news/200508/29/a_strong_dose_of_regulation_set_to_shake_up_pharmaceuticals_sector.page</link><description><![CDATA[Companies operating in the pharmaceuticals and medical devices sectors will be forced to review their business practices if proposed changes to the regulatory regime under which they operate are passed through Federal Parliament, according to a leading corporate lawyer.]]></description><pubDate>Mon, 29 Aug 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050715/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20050715/home.page</link><description><![CDATA[This issue includes: Government signals tighter regulation of complementary medicines; Clinical trials under the Microscope; Proposed new model for the scheduling of medicines and poisons; Quick dose; Deep vein thrombosis - an "accident" or just bad luck?; ACCC v Baxter Healthcare Pty Limited [2005] FCA 581; Oh my Lord! - The House of Lords clarifies UK patent law; Claim construction and fair basis considered; Extending the term of a pharmaceutical patent; The experimental use exception to patent infringement - a preview;]]></description><pubDate>Fri, 15 Jul 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/news/200503/07/clayton_utz_lawyer_calls_for_support_for_patent_law_clarity.page</guid><title><![CDATA[Clayton Utz lawyer calls for support for patent law clarity]]></title><link>http://www.claytonutz.com/publications/news/200503/07/clayton_utz_lawyer_calls_for_support_for_patent_law_clarity.page</link><description><![CDATA[Unless Australia's patent laws are changed the development of its R&D industry may be under threat - and time is running out for those who might be impacted to make their voices heard on the issue, says leading intellectual property lawyer and Clayton Utz partner Wayne Condon.]]></description><pubDate>Mon, 07 Mar 2005 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20041122/home.page</guid><title><![CDATA[Life Sciences Insights]]></title><link>http://www.claytonutz.com/publications/newsletters/life_sciences_insights/20041122/home.page</link><description><![CDATA[This issue includes: Future regulation of cell and tissue therapies; ALRC report: gene patenting and human health; Proposed changes to medicine labelling requirements following the Pan recall; ASX paves the way for self-regulation of the biotech industry; International recognition for our Life Sciences team;]]></description><pubDate>Mon, 22 Nov 2004 00:00:00 EST</pubDate></item><item><guid>http://www.claytonutz.com/docs/FTAReport_2.pdf</guid><title><![CDATA[Free Trade Agreement Report]]></title><link>http://www.claytonutz.com/docs/FTAReport_2.pdf</link><description><![CDATA[Australia and the United States of America completed negotiations to enter into their Free Trade Agreement on 8 February 2004 and signed it on 18 May. This is our initial analytical overview.]]></description><pubDate>Fri, 02 Apr 2004 00:00:00 EST</pubDate></item></channel></rss>